Login to Your Account

Georgia Life Sciences Summit

'To Help or to Suppress,' That Is the Immunotherapy Question

By Jennifer Boggs

Wednesday, September 28, 2011
ATLANTA – Caught between waning investor dollars and a government calling for reduced health care spending, the biotech industry is under more pressure than ever to innovate; the days when firms could create a follow-on molecule that offers only incremental improvements to existing therapies are over.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription